67-6

47/93

) Asao T, Takahashi F, Takahashi K: Resis-tance to molecularly targeted therapy in non- small-cell lung cancer. Respir Investig. 2019; 57: 20-26.) Shukuya T, Takahashi K: Germline muta-tions in lung cancer. Respir Investig. 2019; 57: cases in one family. PLoS One. 2019; 14: e0212370. doi: 10.1371/journal.pone.0212370. 24) Oba S, Inaba Y, Shibuya T, Oshima J, Seyama K, Kobayashi T, Kunugita N, Ino T: Changes in oxidative stress levels during two weeks of smoking cessation treatment and their association with nutritional characteristics in Japanese smokers. Exp Ther Med. 2019; 17: 2757-2764. 25) Tsuyama S, Saito T, Akazawa Y, Yanai Y, Yatagai N, Akaike K, Hayashi T, Suehara Y, Takahashi F, Takamochi K, Hashimoto T, Kajiyama Y, Tsurumaru M, Fukunaga T, Yao T: Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change. Virchows Archiv. 2019; 475: 415-424. 26) Suehara Y, Okubo T, Kurihara T, Hayashi T, Kohsaka S, Kazuno S, Sano K, Hasegawa N, Miura Y, Akaike K, Kim Y, Takamochi K, Takahashi F, Ueno T, Kaneko K, Saito T: Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treat-ment in Giant Cell Tumors of Bone. Proteomics Clin Appl. 2019; 13: e1800147. 27) Miyazaki K, Oyanagi J, Hoshino D, Togo S, Kumagai H, Miyagi Y: Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix. Sci Rep. 2019; 9: 292. 28) Maruyama N, Takai T, Kamijo S, Suchiva P, Ohba M, Takeshige T, Suzuki M, Hara M, Matsuno K, Harada S, Harada N, Nakae S, Sudo K, Okuno T, Yokomizo T, Ogawa H, Okumura K, Ikeda S: Cyclooxygenase inhibi-tion in mice heightens adaptive- and innate-type responses against inhaled protease allergen and IL-33. Allergy. 2019; 74: 2237-2240. 29) Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y: Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. Lung Cancer. 2019; 128: 20-25. 30) Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H, Goto Y, Yoshida K, Ohde Y, Okumura S, Ohashi Y, Kunitoh H: Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan. Jpn J Clin Oncol. 2019; 49: 63-68. 31) Kenmotsu H, Yoh K, Mori K, Ono A, Baba T, Fujiwara Y, Yamaguchi O, Ko R, Okamoto H, Yamamoto N, Ninomiya T, Ogura T, Kato T: Phase II study of nab-paclitaxel + carbo-platin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer Sci. 2019; 110: 3738-3745. 32) Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, Ko R, Hisamatsu Y, Nishino K, Sugimoto T, Miyashita Y, Taka-hashi T, et al: Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol. 2019; 49: 671-675. 33) Okazaki S, Umene K, Yamasaki J, Suina K, Otsuki Y, Yoshikawa M, Minami Y, Masuko T, Kawaguchi S, Nakayama H, Banno K, Aoki D, Saya H, Nagano O: Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma. Cancer Sci. 2019; 110: 3453-3463. 34) Koike K, Beatman EL, Schweitzer KS, Justice MJ, Mikosz AM, Ni K, Clauss MA, Petrache I: Subcutaneous administration of neutral-izing antibodies to endothelial monocyte-acti-vating protein II attenuates cigarette smoke- induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2019; 200: 1113−1125. 35) Kato M, Yamada T, Kataoka S, Arai Y, Miura K, Ochi Y, Ihara H, Koyama R, Sasaki S, Takahashi K: Prognostic differences among patients with idiopathic interstitial pneumo-nias with acute exacerbation of varying pathogenesis: a retrospective study. Respir Res. 2019 Dec 18; 20: 287.〈Reviews〉 1 2555